Stock 950 LEE'S PHARMACEUTICAL HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lee's Pharmaceutical Holdings Limited

Equities

950

KYG5438W1116

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
1.08 HKD -0.92% Intraday chart for Lee's Pharmaceutical Holdings Limited -6.90% -29.41%
Apr. 19 Lee’s Pharmaceutical's 2023 Profit Slumps 67% MT
Mar. 26 Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 2,599 2,764 1,961 959.8 900.9 635.9 -
Enterprise Value (EV) 1 1,991 2,506 1,950 934 900.9 635.9 635.9
P/E ratio - - - - - - -
Yield 1.27% 1.23% 1.83% 1.23% - 2.78% -
Capitalization / Revenue 2.13 x 2.27 x 1.55 x 0.78 x 0.86 x 0.5 x 0.44 x
EV / Revenue 2.13 x 2.27 x 1.55 x 0.78 x 0.86 x 0.5 x 0.44 x
EV / EBITDA 13.2 x 9.85 x 0.88 x 4.2 x - 2.63 x 6.17 x
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book 1.14 x 1.29 x 0.8 x 0.5 x - - -
Nbr of stocks (in thousands) 587,920 588,125 588,835 588,835 588,835 588,835 -
Reference price 2 4.420 4.700 3.330 1.630 1.530 1.080 1.080
Announcement Date 3/26/20 3/30/21 3/29/22 3/30/23 3/26/24 - -
1HKD in Million2HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 1,219 1,217 1,266 1,233 1,053 1,278 1,461
EBITDA 1 196.2 280.6 2,216 228.8 - 241.4 103.1
EBIT 1 141.5 153.1 2,069 76.3 42.68 105 103.1
Operating Margin 11.61% 12.58% 163.4% 6.19% 4.05% 8.22% 7.05%
Earnings before Tax (EBT) - - - - - - -
Net income - - - - - - -
Net margin - - - - - - -
EPS - - - - - - -
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 0.0560 0.0580 0.0610 0.0200 - 0.0300 -
Announcement Date 3/26/20 3/30/21 3/29/22 3/30/23 3/26/24 - -
1HKD in Million2HKD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position 607 258 10.4 25.8 - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) 5.57% 5.82% 86.1% 2.34% - 4.21% 3.99%
ROA (Net income/ Total Assets) - - - - - - -
Assets - - - - - - -
Book Value Per Share 3.880 3.660 4.190 3.270 - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 3/26/20 3/30/21 3/29/22 3/30/23 3/26/24 - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
1.08 HKD
Average target price
1 HKD
Spread / Average Target
-7.41%
Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
LEE'S PHARMACEUTICAL HOLDINGS LIMITED Stock Lee's Pharmaceutical Holdings Limited
-29.41% 81.24M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 950 Stock
  4. Financials Lee's Pharmaceutical Holdings Limited